SELLAS Life Sciences Group, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
SELLAS Life Sciences Group, Inc. (SLS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.85 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-11
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.85, a 77.08% increase year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $0.48, a 83.73% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-06-30 was $1.45, a 31.92% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $2.95, a 38.41% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.85, a 77.08% increase from fiscal 2024.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $0.48, a 83.33% decline from fiscal 2023.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $2.88, a 36.28% decline from fiscal 2022.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $4.52, a 35.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.85 10-K · filed 2026-03-19 | |||||||
| 2025-09-30 | $0.85 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | $0.85 10-Q · filed 2026-08-11 | |||||||
| 2025-03-31 | $0.85 10-Q · filed 2026-05-12 | |||||||
| 2024-12-31 | $0.48 10-K · filed 2026-03-19 | |||||||
| 2024-09-30 | $0.48 10-Q · filed 2025-11-12 | |||||||
| 2024-06-30 | $0.48 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | $0.48 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | $2.88 10-K · filed 2025-03-20 | |||||||
| 2023-09-30 | $2.88 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | $1.45 10-Q · filed 2024-08-13 | $2.88 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $2.95 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | $4.52 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | $2.78 10-Q · filed 2023-11-09 | $4.52 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | $2.13 10-Q · filed 2023-08-10 | $4.76 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | $4.79 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | $6.98 10-K · filed 2023-03-16 | |||||||
| 2021-09-30 | $8.09 10-Q · filed 2022-11-14 | $6.99 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $6.89 10-Q · filed 2022-08-11 | $6.97 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | $6.98 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $1.53 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-13 | $1.53 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | $1.35 10-Q · filed 2021-08-12 | $1.53 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $1.54 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | $54.00 10-K · filed 2021-03-23 | |||||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-13 | $54.00 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-13 | $54.00 10-Q · filed 2020-08-13 | $1.08 10-Q · filed 2019-08-14 | |||||
| 2019-03-31 | $54.00 10-Q · filed 2020-05-14 | $1.08 10-Q · filed 2019-05-15 | ||||||
| 2018-12-31 | $186.50 10-K · filed 2020-03-13 | $3.73 10-K · filed 2019-03-22 | ||||||
| 2018-09-30 | $186.50 10-Q · filed 2019-11-14 | $3.73 10-Q · filed 2018-11-14 | ||||||
| 2018-06-30 | $3.89 10-Q · filed 2019-08-14 | $3.73 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $3.70 10-Q · filed 2019-05-15 | |||||||
| 2017-09-30 | $1.15 10-Q · filed 2017-11-09 | |||||||
| 2017-06-30 | $0.54 10-Q · filed 2017-08-14 | $1.15 10-Q · filed 2017-08-14 | ||||||
| 2017-03-31 | $1.45 10-Q · filed 2017-05-10 | |||||||
| 2016-12-31 | $6.09 10-K · filed 2017-03-15 | |||||||
| 2016-09-30 | $0.45 10-Q · filed 2016-11-09 | $0.51 10-Q · filed 2016-11-09 | ||||||
| 2016-06-30 | $1.36 10-Q · filed 2016-08-09 | $0.86 10-Q · filed 2016-08-09 | ||||||
| 2016-03-31 | $11.20 10-Q · filed 2017-05-10 | $0.56 10-Q · filed 2016-05-10 | ||||||
| 2015-12-31 | $21.40 10-K · filed 2017-03-15 | $1.07 10-K · filed 2016-03-10 | ||||||
| 2015-09-30 | $1.14 10-Q · filed 2015-11-09 | |||||||
| 2015-06-30 | $1.09 10-Q · filed 2015-08-06 | $1.14 10-Q · filed 2015-08-06 | ||||||
| 2015-03-31 | $1.16 10-Q · filed 2015-05-07 | |||||||
| 2014-12-31 | $1.74 10-K/A · filed 2016-04-15 | |||||||
| 2014-09-30 | $1.78 10-Q · filed 2014-11-05 | $1.79 10-Q · filed 2014-11-05 | ||||||
| 2014-06-30 | $1.43 10-Q · filed 2014-08-11 | $1.79 10-Q · filed 2014-08-11 | ||||||
| 2014-03-31 | $5.19 10-Q · filed 2014-05-06 | |||||||
| 2013-12-31 | $1.98 8-K · filed 2015-12-04 | |||||||
| 2013-09-30 | $1.28 10-Q/A · filed 2013-11-07 | |||||||
| 2013-06-30 | $1.63 10-Q · filed 2013-08-09 | $1.28 10-Q · filed 2013-08-09 | ||||||
| 2013-03-31 | $1.16 10-Q · filed 2014-05-06 | |||||||
| 2012-12-31 | $0.70 10-K · filed 2014-03-17 | |||||||
| 2012-09-30 | $1.23 10-Q · filed 2012-11-13 | $0.59 10-Q · filed 2012-11-13 | ||||||
| 2012-06-30 | $1.06 10-Q · filed 2012-08-14 | $0.56 10-Q · filed 2012-08-14 | ||||||
| 2011-12-31 | $0.89 10-K · filed 2013-03-12 | |||||||
| 2011-09-30 | $0.66 10-Q · filed 2012-11-13 | $0.91 10-Q · filed 2012-11-13 | ||||||
| 2011-06-30 | $1.01 10-Q · filed 2012-08-14 | $1.18 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |